# US 2022/0056453 A1 · Compositions and methods to treating hemoglobinopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0056453 A1
- Document ID: US20220056453A1
- Status: Published application
- Kind: A1
- Application number: 17/404,576
- Filed: 2021-08-17
- Published: 2022-02-24
- Earliest claimed: 2014-04-25
- Assignees: Children's Medical Center Corporation
- Applicants: The Children's Medical Center Corporation
- Inventors: Michael MILSOM; David A. WILLIAMS; Richard GREGORY
- Web page: https://patentgrep.com/patent/US20220056453A1

## CPC

- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 7/06: Antianaemics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2740/10032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2740/10043: viral genome or elements thereof as genetic vector
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Embodiments herein provide specially designed synthetic BCL11A-targeting microRNAs for RNA polymerase II expression, and methods of use to treat hemoglobinopathies such as sickle cell disease or thalassemia by increasing the expression levels of fetal hemoglobin levels.

## Claims

### Claim at position 1

1-80. (canceled)

### Claim 81

A lentiviral vector comprising a synthetic BCL11A microRNA comprising:
a) a first BCL11A segment, a loop segment; and
b) a second BCL11A segment arranged in tandem in a 5′ to 3′ direction,
wherein the loop segment is between and directly linked to the first and second BCL11A segments,
wherein the first BCL11A segment starts with a -GCGC- at the 5′ end and the second BCL11A segment ends with a -GCGC- at the 3′ end, and
wherein the first BCL11A segment is complementary to the second BCL11A segment so that the first and second BCL11A segments base pair to form a hairpin loop with the loop segment forming the loop portion of the hairpin loop thus formed.

### Claim 82 (depends on 81)

The lentiviral vector of claim 81, wherein the lentiviral vector is derived from a lentivirus selected from the group consisting of: human immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus type 2 (HIV-2), caprine arthritis-encephalitis virus (CAEV), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), bovine immune deficiency virus (BIV), and simian immunodeficiency virus (SIV).

### Claim 83 (depends on 81)

The lentiviral vector of claim 81, further comprising a spleen focus-forming virus promoter, a tetracycline-inducible promoter, or a β-globin locus control region and a β-globin promoter.

### Claim 84 (depends on 81)

The lentiviral vector of claim 81, wherein the first and second BCL11A segments of the synthetic BCL11A microRNA are about 18 to 25 nucleotides long.

### Claim 85 (depends on 81)

The lentiviral vector of claim 81, wherein the first BCL11A segment of the synthetic BCL11A microRNA contains a sequence derived from a BCL11A mRNA sequence.

### Claim 86 (depends on 81)

The lentiviral vector of claim 81, wherein the first BCL11A segment of the synthetic BCL11A microRNA comprises the nucleotide sequence set forth in any one of SEQ ID NOs: 57, 58, 59, 60, 61, 62, 63, 64, and 65.

### Claim 87 (depends on 81)

The lentiviral vector of claim 81, wherein the first BCL11A segment of the synthetic BCL11A microRNA comprises the nucleotide sequence set forth in SEQ ID NO: 61.

### Claim 88 (depends on 81)

The lentiviral vector of claim 81, wherein the loop segment of the synthetic BCL11A microRNA is derived from a microRNA.

### Claim 89 (depends on 81)

The lentiviral vector of claim 81, wherein the loop segment of the synthetic BCL11A microRNA is derived from a microRNA selected from the group consisting of: miR-142, miR-155, miR-181 and miR-223.

### Claim 90 (depends on 81)

The lentiviral vector of claim 81, wherein the loop segment of the synthetic BCL11A microRNA is derived from miR-223.

### Claim 91 (depends on 81)

The lentiviral vector of claim 81, wherein the loop segment of the synthetic BCL11A microRNA comprises the polynucleotide sequence set forth in SEQ ID NO: 68.

### Claim 92 (depends on 81)

The lentiviral vector of claim 81, wherein the synthetic BCL11A microRNA comprises a polynucleotide sequence set forth in any one of SEQ ID NOs: 34, 35, 36, 37, 38, 39, 40, 41, and 42.

### Claim 93 (depends on 81)

The lentiviral vector of claim 81, wherein the synthetic BCL11A microRNA comprises a polynucleotide sequence set forth in SEQ ID NO: 39.

### Claim 94 (depends on 81)

A composition comprising the lentiviral vector of claim 81.

### Claim 95 (depends on 81)

A pharmaceutical composition comprising the lentiviral vector of claim 81 and a pharmaceutically acceptable carrier or diluent.
